A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to ...

The IAEA is launching a year-long coordinated research project to develop computed tomography-based guidelines on prostate cancer contouring — a critical step in the cancer treatment process that ...

The FDA approved updated labeling for Talzenna plus Xtandi for HRR gene-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial results. The TALAPRO-2 trial showed a ...

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic ...